supplementary figure 1 ea: 0b: 1+ c: 2+d: 3+ e: normal bronchial epithelium a c b d
TRANSCRIPT
Supplementary Figure 1
E A: 0 B: 1+
C: 2+ D: 3+
E: Normal bronchial epithelium
A
C
B
D
ID Gender Histological Type$ EGFR Mutation Status Treatment BOR* HGF T790M MET AmplificationNC-1 M Ad L858R Gefitinib SD 0 - -NC-2 M Ad L858R Gefitinib SD 160 - -NC-3 M Ad L858R Gefitinib PD 160 - -NC-4 M Ad L858R Erlotinib SD 110 - -NC-6 F Ad G719S Gefitinib SD 120 - -NC7 M Ad Exon 19 del Gefitinib SD 150 - -NC-9 M Ad L858R Gefitinib PD 180 - -NC-10 M NSCLC L858R Gefitinib PD 90 - -NC-11 F Ad L858R Gefitinib SD 200 - -NC-12 F Ad L858R Gefitinib PD 120 - -AC1 F Ad Exon 19 del Gefitinib SD 50 - -AC2 M Ad Exon 19 del Gefitinib SD 100 # - -AC4 M Ad Exon 19 del Gefitinib SD 190 - -AC8 F Ad L858R Gefitinib SD 140 - -AC10 F Ad L858R Gefitinib PD 150 - -AC11 M Ad L858R Gefitinib PD 130 - -AC12 F Ad L858R Gefitinib PD 120 - +OF-1 M Ad Exon 19 del Gefitinib SD 0 # - -OF-2 F Ad L858R Gefitinib PD 0 - -OF-3 F Ad L858R Gefitinib PD 40 - -OF-4 M Ad L858R Gefitinib SD 110 - -KG-1 F Ad L858R Gefitinib SD 0 - -KG-10 M Ad Exon 19 del Gefitinib SD 195 - -KG-15 M AdSq L858R Gefitinib SD 110 - -KG-21 F Ad L858R Gefitinib SD 230 - -KG-26 M Ad L858R Gefitinib SD 0 - -OC-1 M Sq Exon 19 del Gefitinib SD 140 - -OC-2 M Ad Exon 19 del Erlotinib SD 0 - -OC-3 F Ad Exon 19 del Erlotinib SD 210 - -OC-4 M Ad G719A Erlotinib PD 160 - -OC-6 M Ad Exon 19 del Gefitinib PD 20 - -OC-7 M Sq L858R Erlotinib SD 170 - -OC-10 F Ad L858R Erlotinib SD 180 - -OC-15 M Ad L858R Erlotinib PD 140 - -OC-16 F Ad L858R+Exon 19 del Gefitinib SD 150 - -OC-18 M Ad Exon 19 del Gefitinib SD 200 - +
OK-2-1 F Ad L858R Gefitinib SD 270 -
(D761Y+)-
OK-2-2 125 -
(D761Y+)-
OK3 M Ad Exon 19 del Vandetanib SD 280 - -OK5 M Ad L858R Gefitinib SD 170 - -OK6 M Ad L858R Gefitinib PD 200 - -OK7 F La Exon 19 del Gefitinib PD 270 - -AC21 M Ad L858R Gefitinib PD 230 - -AC22 F Ad L858R Gefitinib PD 200 - -TB3 F Ad L858R Gefitinib PD 240 - -
Supplementary Table 1. Summary of Tumors with Intrinsic Resistance
$ Ad: adeno; AdSq: adenosquamous; Sq squamous; La: large; *BOR: best overall response; # High-level HGF expression was detected in stromal cells.
ID Gender Histological Type$ EGFR Mutation Status Treatment BOR* HGF T790M MET Amplification
KG-2 M Ad Exon 19 del Gefitinib PR 80 - -
KG-3 F Ad L858R Gefitinib PR 50 - -
KG-4 M Ad Exon 19 del Gefitinib PR 150 - -
KG-5 M Ad L858R Gefitinib PR 200 - -
KG-7 M Ad L858R Gefitinib PR 150 - -
KG-8 F Ad L858R Gefitinib PR 140 - -
KG-9 F Ad Exon 19 del Gefitinib PR 80 - -
KG-11 F Ad Exon 19 del Gefitinib PR 180 - -
KG-12 F Ad Exon 19 del Gefitinib PR 160 - -
KG-13 M Ad Exon 19 del Gefitinib PR 150 - -
KG-14 M Ad L858R Gefitinib PR 80 - -
KG-16 F Ad L858R Gefitinib PR 60 - -
KG-17 F Ad Exon 19 del Gefitinib PR 220 - -
KG-18 M Ad L858R Gefitinib PR 80 - -
KG-19 F Ad L858R Gefitinib PR 10 - -
KG-20 F Ad L858R Gefitinib PR 120 - -
KG-22 F Ad L858R Gefitinib PR 0# - -
KG-23 F Ad Exon 19 del Gefitinib PR 75 - -
KG-24 F Ad L858R Gefitinib PR 100 - -
KG-25 F Ad Exon 19 del Gefitinib PR 0 - -
KG-27 M Ad Exon 19 del Gefitinib PR 150 - -
OC-5 M Ad L858R Gefitinib PR 190 - -
OC-8 F Ad L858R Erlotinib PR 180 - -
OC-9 F Ad Exon 19 del Erlotinib PR 160 - -
OC-11 F Ad L858R Gefitinib PR 100 - -
OC-12 F Ad Exon 19 del ＋ L858R Erlotinib PR 80 - -
OC-13 F Ad Exon 19 del Erlotinib PR 130 - -
OC-14 F Ad Exon 19 del Gefitinib PR 120 - -
OC-17 M Ad L858R Gefitinib PR 80 - -
Supplementary Table 2. Summary of Sensitive Tumors
$ Ad: adeno; *BOR: best overall response; # High-level HGF expression was detected in the stroma.